BrainStorm Cell Therapeutics

BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market
BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market
Fierce Biotech
BrainStorm Cell Therapeutics
layoffs
FDA
ALS
NurOwn
Flag link:
BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application
BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application
Fierce Biotech
BrainStorm Cell Therapeutics
ALS
FDA
NurOwn
Flag link:
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
BioSpace
FDA
BrainStorm Cell Therapeutics
NurOwn
Seelos Therapeutics
Takeda
Clene
Flag link:
FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote
FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote
BioSpace
BrainStorm Cell Therapeutics
FDA
ALS
NurOwn
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Fierce Biotech
BrainStorm Cell Therapeutics
ALS
cell therapy
Biogen
NurOwn
Flag link:
9 Highly Anticipated FDA Decisions in Second Half of 2023
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Flag link:
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
BioPharma Dive
BrainStorm Cell Therapeutics
FDA
NurOwn
cell therapy
ALS
Flag link:
BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn
BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn
BioSpace
BrainStorm Cell Therapeutics
NurOwn
ALS
FDA
Flag link:
BrainStorm Vows to Push for Adcomm Meeting on NurOwn in ALS
BrainStorm Vows to Push for Adcomm Meeting on NurOwn in ALS
BioSpace
BrainStorm Cell Therapeutics
NurOwn
ALS
FDA
Flag link:
Not once, but twice: BrainStorm shares tumble as FDA again knocks back ALS drug
Not once, but twice: BrainStorm shares tumble as FDA again knocks back ALS drug
Fierce Biotech
BrainStorm Cell Therapeutics
ALS
FDA
NurOwn
Flag link:
BrainStorm Brings MS Data on Heels of ALS BLA Announcement
BrainStorm Brings MS Data on Heels of ALS BLA Announcement
BioSpace
BrainStorm Cell Therapeutics
NurOwn
multiple sclerosis
MS
Flag link:
Highlighted by Amylyx, the ALS Space is Gaining Momentum
Highlighted by Amylyx, the ALS Space is Gaining Momentum
BioSpace
ALS
AMX0035
Amylyx
GeNeuro
NeuroSense Therapeutics
BrainStorm Cell Therapeutics
Flag link:
BrainStorm’s ALS Drug Heads to the FDA with Correction to Phase III Analyses
BrainStorm’s ALS Drug Heads to the FDA with Correction to Phase III Analyses
BioSpace
BrainStorm Cell Therapeutics
NurOwn
ALS
FDA
clinical trials
Flag link:
NurOwn: A Study in the Complexity of ALS Trials
NurOwn: A Study in the Complexity of ALS Trials
BioSpace
BrainStorm Cell Therapeutics
NurOwn
ALS
clinical trials
Flag link:
BrainStorm Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis
BrainStorm Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis
BioSpace
BrainStorm Cell Therapeutics
MS
clinical trials
multiple sclerosis
Flag link:
FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit
FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit
MedCity News
BrainStorm Cell Therapeutics
ALS
stem cell therapy
clinical trials
FDA
Flag link:
Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway
Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway
Endpoints
BrainStorm Cell Therapeutics
ALS
cell therapy
FDA
Flag link:
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
Flag link:
ALS drug maker walks back plan to profit from right-to-try law following heavy criticism
ALS drug maker walks back plan to profit from right-to-try law following heavy criticism
Stat
BrainStorm Cell Therapeutics
right-to-try laws
ALS
clinical trials
NurOwn
Flag link:

Pages